Cell death induced by the Fas/Fas ligand pathway and its role in pathology

Immunology and Cell Biology

Volumn 77, Issue 4, 1999, Pages 312-317

  Waring, Paul ^a,b   Müllbacher, Arno ^a  

^a Biology and Environment   (Australia)

^b Div of Immunology and Cell Biology   (Australia)

Author keywords

Cell death; DNA damage; Fas receptor; Up regulation

Indexed keywords

CASPASE; FAS ANTIGEN; PROTEIN P53;

ANTIGEN EXPRESSION; APOPTOSIS; CELL DEATH; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; ENZYME ACTIVATION; IMMUNE SYSTEM; RECEPTOR UPREGULATION; REVIEW;

EID: 0032777102     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1999.00837.x     Document Type: Review

References (88)

1. 1 Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
2. 2 Schulzeosthoff K, Ferrari D, Los M, Wesselbourg S, Peter ME. Apoptosis signalling by death receptors. Eur. J. Biochem. 1998; 254: 439-59.
3. 3 Trauth BC, Klas C, Peters AMJ et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-5.
4. 4 Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal anti-body (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989; 169: 1747-56.
5. 5 Watanabe-Fukunaga R, Brannan CI, Itoh N et al. The cDNA structure, expression and chromosomal assignment of the mouse Fas, antigen. J. Immunol. 1992; 148: 1274-9.
6. 6 Ashkenazi A, Dixit VM. Death receptors: Signalling and modulation. Science 1998; 281: 1305-8.
7. 7 Magnusson C, Vaux DL. Signalling by CD95 and TNF receptors: Not only life and death. Immunol. Cell Biol. 1999; 77: 41-6.
8. 8 Krammer PH. The CD95 (APO-1/Fas) CD95L system. Toxicol. Lett. 1998; 103: 131-7.
9. 9 Osborne BA. Apoptotic signalling pathways in lymphocytes. In: Lochshin RA, Zakeri Z, Tilly JL (eds). When Cells Die: A Comprehensive Evaluation of Apoptosis and Programmed Cell Death. New York: Wiley-Liss, 1998; 245-66.
10. 10 Nicholson DW, Thornberry NA. Caspases: Killer proteases. Trends Biochem. Sci. 1997; 22: 299-306.
11. 11 Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-aclivated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.
12. 12 Alnemri ES, Livingston DJ, Nicholson DW et al. Human ICE/CED-3 protease nomenclature. Cell 1996; 87: 171.
13. 13 Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE. A novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death inducing signalling complex. Cell 1996; 85: 817-27.
14. 14 Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO-1 contains a sequence motif related to the death domain. J. Biol. Chem. 1995; 270: 7795-8.
15. 15 Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-12.
16. 16 Barry M, McFadden G. Apoptosis regulators from DNA viruses. Curr. Opin. Immunol. 1998; 10: 422-30.
17. 17 Turner PC, Musy PY, Moyer RW. Poxvirus Serpins. In: McFadden GF (ed.). Virorecepters, Virokines und Related Immune Modulators Encoded by DNA Viruses. Austin: RG Landes Company, 1994; 67-88.
18. 18 Clem RJ, Fechheimer M, Miller LK. Prevention of apoptosis by a baculovirus gene during infection of insect cells. Science 1991; 254: 1388-90.
19. 19 Thome M, Schneider P, Hofmann K et al. Viral FLICE-inhibitory proteins (FLIPS) prevent apoptosis induced by death receptors. Nature 1997; 386: 517-21.
20. 20 Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-5.
21. 21 Srinivasula SM, Ahmed M, Ottilie S et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFRI-induced apoptosis. J. Biol. Chem. 1997; 272: 18542-5.
22. 22 Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D. CASH, a novel caspase homolog with death effector domains. J. Biol. Chem. 1997; 272: 19641-4.
23. 23 Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor and CD95 induced apoptosis. J. Biol. Chem. 1997; 272: 17255-7.
24. 24 Rasper DM, Vaillancourt JP, Hadano S et al. Cell death attenuation by 'usurpin', a mammalian DED-caspase homolog that precludes caspase 8 recruitment and activation by the CD95 receptor complex. Cell Death Differ. 1998; 5: 271-88.
25. 25 Inohara N, Koseki T, Hu Y, Chen S, Nunez G. CLARP, a death effector domain containing protein interacts with caspase 8 and regulates apoptosis. Proc. Natl Acad. Sci. USA 1997; 94: 10 717-22.
26. 26 Shu HB, Halpin DV, Goeddel DV. Casper is a FADD and caspase related inducer of apoptosis. Immunity 1997; 6: 751-63.
27. 27 Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
28. 28 Turner PC, Moyer RW. Control of apoptosis by poxviruses. Semin. Virol. 1998; 8: 453-69.
29. 29 Ray CA, Black RA, Kronheim SR et al. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992; 69: 597-604.
30. 30 Tewari M, Quan LT, O'Rourke et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81: 801-9.
31. 31 Medema J, Scaffidi C, Kischkel F et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997; 16: 2794-804.
32. 32 Nicholson DW, Ali A, Thornberry NA et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
33. 33 Zhou Q. Snipas S, Orth K, Muzio M, Dixit VM, Salvesen GS. Target protease spccifieity of the viral scrpin CrmA. Analysis of five caspases. J. Biol. Chem. 1997; 272: 7797-800.
34. 34 Tewari M, Telford WG, Miller RA, Dixit VM. CrmA, a poxvirus-encoded serpin, inhibits cytotoxic T-lymphocyte-mediated apoptosis. J. Biol. Chem. 1995; 270: 22705-8.
35. 35 Macen JL, Garner RS, Musy PY et al. Differential inhibition of Fas-and granule-mediated cytolysis pathways by the orthopoxvirus cytokine response modifier A/SPI-2 and SPI-1 protein. Proc. Natl Acad. Sci. USA 1996; 93: 9108-13.
36. 36 Kettle S, Alcami A, Khanna A, Ehret R, Jassoy C, Smith GL. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β-converting enzyme and protects virus-infected cells from TNF-and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J. Gen. Virol. 1997; 78: 677-85.
37. 37 Müllbacher A, Wallich R, Moyer RW, Simon MM. Poxvirus encoded serpins do not prevent cytolytic T cell mediated recovery from primary infections. J. Immunol. 1999; 162: in press.
38. 38 Xue D, Horvitz HR. Inhibition of the Caenorhabditis elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein. Nature 1995; 377: 248-51.
39. 39 Deveraux Q, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-4.
40. 40 Stegh AH, Schickling O, Ehret A et al. DEDD, a novel effector domain-containing protein, targeted to the nucleolus. EMBO J. 1998; 17: 5974-86.
41. 41 Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 1995; 16: 569-74.
42. 42 Dhein J, Walczak H, Baumler C, Debatin K-M, Krammer PH. Automne T-cell suicide mediated by APO-1/ (Fas/CD95). Nature 1995; 373: 438-41.
43. 43 Brunner T, Mogil RJ, LaFace D et al. Cell autonomous Fas (CD95)/Fas ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-4.
44. 44 Ju S-T, Panka DJ, Cul H et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-8.
45. 45 Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferative disorders in mice explained by detects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-17.
46. 46 Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-76.
47. 47 Russell JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a detect in antigen-stimulated suicide. Proc. Natl Acad. Sci. USA 1993; 90: 4409-13.
48. 48 Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
49. 49 Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
50. 50 Krammer PH. The tumor strikes back - new data on the expression of the CD95 (Apo-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology. Cell Death Differ, 1997; 4: 363-4.
51. 51 O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counter attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996; 184: 1075-82.
52. 52 Kagi D, Vignaux F, Lederman B et al. Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity. Science 1994; 265: 528-30.
53. 53 Henkart PA. Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity 1994; 1: 343-6.
54. 54 Young JD-E, Podack ER, Chon ZA. Properties of purified poreforming protein (perforin 1) isolated from H-2-restricted cytotoxic T cell granules. J. Exp. Med. 1986; 164: 144-55.
55. 55 Shi JF, Mai S, Israels S, Browne K, Trapani JA, Greenberg AH. Granzyme B (GraB) autonomously crosses the cell membrane and perform initiates apoptosis and GraB localization. J. Exp. Med. 1997; 185: 885-66.
56. 56 Simon MM, Hausmann M, Tran T et al. In vitro and ex vivo-derived cytolytic leukocytes from granzyme AxB double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J. Exp. Med. 1997; 186: 1781-6.
57. 57 Froelich CJ, Orth K, Turbov J et al. New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J. Biol. Chem. 1996; 271: 29073-81.
58. 58 Froelich CJ, Dixit VM, Yang X. Lymphocyte granule-mediated apoptosis: Matters of viral mimicry and deadly proteases. Immunol. Today 1998; 19: 30-6.
59. 59 Kagi D, Ledermann B, Burki K et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-7.
60. 60 Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanarama VS, Pahwa S. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMcs from normal individuals. Blood 1993; 82: 3392-400.
61. 61 Conaldi PG, Biancone L, Bottelli A et al. HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and fas upregulation. J. Clin. Invest. 1998; 102: 2041-9.
62. 62 Suzuki A. The dominant role of CPP. 32 subfamily in fas-mediated hepatitis. Proc. Soc. Exp. Biol. Med. 1998; 217: 450-4.
63. 63 Takahara T, Hayashi N, Mita F. et al. Delayed Fas mediated hepatocyte apoptosis during liver regeneration in mice hepatoprotective role of TNF-alpha. Hepatology 1998; 27: 1643-51.
64. 64 Tsutsui H, Matsui K, Kawada N et al. IL-18 accounts for both TNF-alpha and Fas ligand mediated hepatotoxicity pathways in endotoxin-induced liver injury in mice. J. Immunol. 1997; 159: 3961-7.
65. 65 Nishimuramorita Y, Nose M, Inoue T, Yonehara S. Amelioration of systemic autoimmune disease by the stimulation of apoptosis promoting receptor Fas with anti-fas mab. Int. Immunol. 1997; 9: 1793-9.
66. 66 Akasaka Y, Ishikawa Y, Kato S et al. Induction of Fas mediated apoptosis in a human renal epithelial cell line by interferon-gamma - involvement of fas-mediated apoptosis in acute renal rejection. Mod. Pathol. 1998; 11: 1107-14.
67. 67 Kawahara K, Kasai S, Yagita H et al. Critical role of Fas/Fas ligand interaction in CD28-independcnt pathway of allogeneic murine hepatocyte rejection. Hepatology 1997; 26: 944-8.
68. 68 Lin TS, Brunner T, Tietz B et al. Fas ligand-mediated killing by intestinal intraperitoneal lymphocytes - participation in intestinal graft-versus-host disease. J. Clin. Invest. 1998; 101: 570-7.
69. 69 Kanda Y, Tanaka Y, Shirakawa K et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant. 1998; 22: 751-4.
70. 70 Beurton F, Gueret G, Horisberger M, Cheron G, Cresteil T. Transcriptional activation of CYP2C, MxA and Fas in sudden infant death syndrome. Int. J. Mol. Med. 1999; 3: 33-9.
71. 71 Saito I, Haruta K, Shimuta M et al. Fas ligand-mediated exocrinopathy resembling Sjogren's syndrome in mice transgenic for IL-10. J. Immunol. 1999; 162: 2488-94.
72. 72 Fyhr IM, Oldfors A. Upregulation of Fas/Fas ligand in inclusion body myositis. Ann. Neurol. 1998; 43: 127-30.
73. 73 Seidel R, Fang-Kircher S, Bidmon B, Cairns N, Lubec G. Apoptosis-associatcd proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down Syndrome. Neurosci. Lett. 1999; 260: 9-12.
74. 74 Potestio M, Caruso C, Gervasi F et al. Apoptosis and ageing. Mech. Ageing Dev. 1998; 102: 221-37.
75. 75 Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering Fas gene mutations impair apoptosis in humane autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-46.
76. 76 Rieux-Laucat F, Le Diest F, Hivroz C et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-9.
77. 77 Asoh S, Mori T, Hayashi J-I, Ohta S. Expression of the apoptosis-mediator Fas is enhanced by dysfunctional mitochondria. J. Biochem. 1996; 120: 600-7.
78. 78 Friesen C, Herr I, Krammer PH, Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 1996; 2: 574-7.
79. 79 Fulda S, Sieverts H, Friesen C, Herr I, Debatin K-M. The CD95 (APO-1/Fas) system mediates drug induced apoptosis in neuroblastoma cells. Cancer Res. 1997; 57: 3823-9.
80. 80 Micheau O, Solary E, Hammann A, Martin F, Dimancheboitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J. Natl Cancer Inst. 1997; 89: 783-9.
81. 81 Mizutani Y, Okada Y, Yoshida O, Kukumoto M, Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to fas-mediated cytotoxicity. Cancer 1997; 79: 1180-9.
82. 82 Nakamura S, Takeshima M, Nakamura Y, Ohtake S, Matsuda T. Induction of apoptosis in HL60 leukemic cells by anti-cancer drugs in combination with anti-fas monoclonal antibody. Anti-cancer Res. 1997; 17: 173-9.
83. 83 Bose R, Verheij M, Haimovitzfriedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis - an alternative mechanism for generating death signals. Cell 1995; 82: 405-14.
84. 84 Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL. Radiation and stress-induced apoptosis: A role for Fas/Fas ligand interactions. Proc. Natl Acad. Sci. USA 1997; 94: 5750-5.
85. 85 Neumann D, Zierke M, Martin MU. Withdrawal of 2-mercaptoethanol induces apoptosis in a B-cell line via Fas upregulation. J. Cell. Physiol. 1998; 177: 68-75.
86. 86 Owen-Schaub LB, Zhang W, Cusack JC et al. Wild-type human p53 and a temperature sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 1995; 15: 3032-40.
87. 87 Muller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 1997; 99: 403-13.
88. 88 Muller M, Wilder S, Bannasch D et al. p53 activates the CD95 (ASPO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 1998; 188: 2033-45.